GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (FRA:6GJ) » Definitions » Debt-to-Equity

Glaukos (FRA:6GJ) Debt-to-Equity : 0.14 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Debt-to-Equity?

Glaukos's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.0 Mil. Glaukos's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €98.7 Mil. Glaukos's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €732.4 Mil. Glaukos's debt to equity for the quarter that ended in Dec. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Glaukos's Debt-to-Equity or its related term are showing as below:

FRA:6GJ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1   Med: 0.41   Max: 0.83
Current: 0.14

During the past 12 years, the highest Debt-to-Equity Ratio of Glaukos was 0.83. The lowest was 0.10. And the median was 0.41.

FRA:6GJ's Debt-to-Equity is ranked better than
62.55% of 689 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs FRA:6GJ: 0.14

Glaukos Debt-to-Equity Historical Data

The historical data trend for Glaukos's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Debt-to-Equity Chart

Glaukos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 0.65 0.72 0.83 0.14

Glaukos Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.85 0.24 0.24 0.14

Competitive Comparison of Glaukos's Debt-to-Equity

For the Medical Devices subindustry, Glaukos's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glaukos's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Glaukos's Debt-to-Equity falls into.


;
;

Glaukos Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Glaukos's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Glaukos's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos  (FRA:6GJ) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Glaukos Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Glaukos's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Headlines

No Headlines